Clinical trials: Temozolomide, completed
Glioblastoma
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
The purpose of this surveillance is to collect more safety and efficacy data in "non-study" patients during concomitant and adjuvant temozolomide therapy.
- Trial name
- NCT00704808
- Testing
- Primary surgical treatment, Radiotherapy, Temozolomide
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of nanoparticle albumin-bound rapamycin when given together with temozolomide and irinotecan hydrochloride in treating pediatric patients with solid tumors that have come…
- Conditions
- Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT02975882
- Testing
- Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 33 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme
FET-PET Directed Simultaneous In-field Boost for Primary GBM
The combination of anatomical MRI examination with functional examination of tissue metabolic activity such as FET-PET (PET using the radiotracer - 18F-fluoro-ethyl-tyrosine) is a valuable tool to determine the actual tumor…
- Trial name
- dualFETboost (NCT04790097)
- Testing
- Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost
- Where
- Poland
- Volunteers
- 17 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Glioblastoma Multiforme, Glioma
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors.
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02502708
- Testing
- Indoximod, Temozolomide, Conformal Radiation
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- NewLink Genetics Corporation
Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places…
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma
- Trial name
- NCT03728361
- Testing
- Nivolumab, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Dwight Owen
Glioblastoma
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with recurrent or refractory Glioblastoma
- Trial name
- METT (NCT03243851)
- Testing
- Temozolomide+Metformin
- Where
- 12 sites in South Korea
- Volunteers
- 81 people
- Sponsor
- Yong-Kil Hong
CNS Tumor, Adult
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
RATIONALE : IMA 950 is multi tumour-associated peptides (TUMAPs) vaccine, these peptides have been identified on primary glioblastoma multiforme (GBM) cells.
- Trial name
- NCT01920191
- Testing
- IMA 950, Poly ICLC, Immunomonitoring
- Where
- Switzerland
- Volunteers
- 19 people
- Sponsor
- University Hospital, Geneva
Naive Unresectable Glioblastoma
Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma
Treatment of glioblastoma (GBM) is based on surgery when possible, and chemoradiation with temozolomide, which became a standard since the EORTC study (Stupp, 2005).
- Trial name
- TemAvIr (NCT01022918)
- Testing
- Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures), Temodal/radiotherapy
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Centre Georges Francois Leclerc
Melanoma
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
This research is being done because melanoma in the brain is very difficult to treat because it does not respond to radiation or to chemotherapy, such as temozolomide.
- Trial name
- MEL0107 (NCT01048554)
- Testing
- Temozolomide, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Glioblastoma Multiforme
Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
The purpose of this study is to explore the efficacy and safety of Atorvastatin in combination with multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide in patients with newly…
- Trial name
- ART (NCT02029573)
- Testing
- Atorvastatin, Temozolomide, Radiotherapy
- Where
- Saudi Arabia
- Volunteers
- 36 people
- Sponsor
- King Fahad Medical City
Brain Tumor
A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.
- Trial name
- NCT00584883
- Testing
- ABT 510
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Glioblastoma (GBM) is the most frequent primary brain tumor and the brain tumor with the poorest prognosis. The current treatment relies on surgical resection of gross tumor followed by radiochemotherapy and adjuvant therapy with…
- Trial name
- UCPVax-Glio (NCT04280848)
- Testing
- UCPVax, Temozolomide
- Where
- 5 sites in France
- Volunteers
- 67 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon